CytRx
Corporation
11726 San Vicente Boulevard, Suite 650
Los Angeles, California 90049
July 12, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
Securities and Exchange Commission
Washington, D.C. 20549
Re: | CytRx Corporation |
Registration Statement on Form S-3, as amended
Filed on April 22, 2021
File No. 333-255431 (the “Registration Statement”)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, CytRx Corporation (the “Company”) hereby respectfully requests acceleration of the effective date of the Registration Statement, as amended, so that it may become effective at 4:00 p.m., Eastern Time, on July 12, 2021, or as soon thereafter as practicable.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours, | ||
CytRx Corporation | ||
By: | /s/ Steven A. Kriegsman | |
Steven A. Kriegsman | ||
Chairman and Chief Executive Officer |
cc: | Rick A. Werner, Esq., Haynes and Boone, LLP |